Zydus Lifesciences has achieved a significant regulatory milestone with the receipt of Establishment Inspection Report (EIR) and approval from the United States Food and Drug Administration (USFDA) for its specialized oncology injectable manufacturing facility. The company made this disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, highlighting the strategic importance of this regulatory achievement.

Regulatory Inspection and Approval Details

The USFDA approval comes following a comprehensive Pre-Approval Inspection (PAI) conducted at the oncology injectable manufacturing site located in SEZ1, Ahmedabad. The inspection specifically focused on the new isolator injectable line, representing a critical component of the facility's manufacturing capabilities.

Strategic Significance for Oncology Manufacturing

The approval of the oncology injectable facility represents a crucial development for Zydus Lifesciences' pharmaceutical manufacturing capabilities. Oncology injectables require specialized manufacturing environments and stringent quality controls due to their critical therapeutic applications in cancer treatment. The new isolator injectable line demonstrates the company's commitment to advanced manufacturing technologies that ensure product safety and efficacy.

Regulatory Compliance and Market Access

With the successful completion of the USFDA inspection and subsequent approval, the Ahmedabad facility is now positioned to manufacture oncology injectable products for the US market. The EIR confirmation validates that the facility meets the rigorous regulatory requirements set by the USFDA for pharmaceutical manufacturing operations. This approval enhances the company's ability to serve international markets with high-quality oncology products, supporting its growth strategy in specialized therapeutic areas.

Zydus Lifesciences Limited has received favorable news regarding a GST penalty case involving its subsidiary. The pharmaceutical company announced that German Remedies Pharmaceuticals Private Limited (GRPPL), a wholly owned subsidiary, has successfully overturned a penalty order through an appeal process.

GST Penalty Appeal Success

GRPPL had previously received a Demand Order-In-Original imposing a penalty of Rs. 1.66 million for the financial year 2018-19. The penalty was related to alleged excess availment of Input Tax Credit under the Central GST Act. The company had filed an appeal against this order before the Office of Commissioner, Central GST, Appeal Ahmedabad Commissionerate.

Appeal Order Details

The appellate authority has issued an order confirming that the penalty amount under section 74 of the CGST Act, 2017, of Rs. 1.66 million has been completely dropped. The Appeal Order was dated April 1, 2026, and was received by the authorized officials of the company on April 15, 2026, at 10.58 a.m.

Financial Impact Assessment

Zydus Lifesciences has evaluated the impact of this favorable decision and concluded that there is no material impact on the financials, operations, or other activities of either GRPPL or the parent company. The successful appeal represents a positive outcome for the pharmaceutical group, eliminating a potential financial liability.

Corporate Structure Context

German Remedies Pharmaceuticals Private Limited operates as a wholly owned subsidiary of Zydus Healthcare Limited, which is itself a wholly owned subsidiary of Zydus Lifesciences Limited. This multi-tiered structure is common in pharmaceutical companies to manage different business segments and regulatory requirements across various markets and product categories.